Here are four key points:
1. With this partnership, Implanet markets in 17 countries.
2. Implanet will now have access to Australia’s $120 million vertebral fusion market, to offer its Jazz products.
3. Implanet also integrated its Jazz Claw into the Australian Register of Therapeutic Goods.
4. Jazz is designed to treat spinal pathologies with vertebral fusion surgery.
More articles on devices:
Medtronic unveils sacral fracture-treating bone cement — 5 observations
DJO Global unveils Altivate Anatomic Shoulder System: 4 things to know
Why AdvaMed supports AHCA: 6 key reasons
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
